Response to "Critique and Discussion of 'Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose"
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Sunderland, J. J., Graves, S. A., York, D. M., Mundt, C. A., Bartel, T. B. Tags: Letters Source Type: research
Reply to: Potential of 188Re as an Alternative to 177Lu and Dosimetric Consequences
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Cardinale, J., Giesel, F. L., Wensky, C., Rathke, H. G., Haberkorn, U., Kratochwil, C. Tags: Letters Source Type: research
Potential of 188Re as an Alternative to 177Lu and Dosimetric Consequences
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Pretze, M., Kotzerke, J., Freudenberg, R., Brogsitter, C. Tags: Letters Source Type: research
Reply to: Not All Gatekeepers Are Theranostics
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Weber, W. A., Barthel, H., Bengel, F. M., Eiber, M. M., Herrmann, K., Schafers, M. Tags: Letters Source Type: research
Not All Gatekeepers Are Theranostics
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Bailey, D. L. Tags: Letters Source Type: research
[68Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Unterrainer, L. M., Sisk, A. E., Czernin, J., Shuch, B. M., Calais, J., Hotta, M. Tags: Illustrated Post Source Type: research
Preclinical Comparison of the 64Cu- and 68Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [68Ga]Ga-AMTG PET/CT
Conclusion: AMTG is eligible for theranostic use, as labeling with 64Cu and 68Ga, as well as 177Lu (known from previous study), does not have a negative influence on its favorable biodistribution pattern. For this reason, further clinical evaluation is warranted. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Koller, L., Joksch, M., Schwarzenbock, S., Kurth, J., Heuschkel, M., Holzleitner, N., Beck, R., von Amsberg, G., Wester, H.-J., Krause, B. J., Gunther, T. Tags: Basic Science Investigations Source Type: research
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green
Conclusion: SWIRFI sensitivity and ambient light resistance enabled continued tracer clearance tracking with unparalleled SNR and CNR values at video rates for tumor delineation (achieving a tumor-to-muscle ratio above 20). In total, we provide a direct precedent for the democratic translation of an ambient light resistant SWIRFI and pHLIP ICG ecosystem, which can instantly improve tumor resection. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Mc Larney, B. E., Kim, M., Roberts, S., Skubal, M., Hsu, H.-T., Ogirala, A., Pratt, E. C., Pillarsetty, N. V. K., Heller, D. A., Lewis, J. S., Grimm, J. Tags: Basic Science Investigations Source Type: research
Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins
Conclusion: Our data from a gastric cancer xenograft show the utility of HER2-targeted immuno-PET to inform the tumor response to ADC therapies in combination with modulators of cell-surface target availability. Our studies also demonstrate that statins enhance ADC efficacy in both a cell-line and a patient-derived xenograft model in ways that enable a single-dose administration of the ADC. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Brown, E. L., Shmuel, S., Mandleywala, K., Panikar, S. S., Berry, N.-K., Rao, Y., Zidel, A., Lewis, J. S., Pereira, P. M. R. Tags: FEATURED BASIC ARTICLE OF THE MONTH Source Type: research
Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy
Conclusion: To account for the heterogeneous absorbed dose generated from nonuniform intratumoral activity uptake, dosimetry models can estimate the mean necessary activity to reach a sufficient TCP for treatment response. This approach is necessary to accurately evaluate the efficacy of suggested radiopharmaceuticals for therapy. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Mellhammar, E., Dahlbom, M., Vilhelmsson-Timmermand, O., Strand, S.-E. Tags: Basic Science Investigations Source Type: research
Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy
Conclusion: The data of this study indicate the promising potential of 161Tb in combination with SibuDAB for RLT of prostate cancer. Future clinical studies using 161Tb-based RLT will shed light on a potential clinical benefit of 161Tb over 177Lu. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Tschan, V. J., Busslinger, S. D., Bernhardt, P., Grundler, P. V., Zeevaart, J. R., Koster, U., van der Meulen, N. P., Schibli, R., Muller, C. Tags: Basic Science Investigations Source Type: research
Membrane and Nuclear Absorbed Doses from 177Lu and 161Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting--A Monte Carlo Study
Conclusion: To eradicate tumor cell clusters, 161Tb may be a better candidate than 177Lu. Heterogeneous cell targeting can lead to substantial heterogeneities in absorbed doses. Dual targeting was helpful in reducing dose heterogeneity and should be explored in preclinical and clinical studies. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Larouze, A., Alcocer-Avila, M., Morgat, C., Champion, C., Hindie, E. Tags: Basic Science Investigations Source Type: research
Choosing the Right Metrics for Evaluation of Radiopharmaceutical Therapy Dosimetry Methodologies
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Scheuermann, J. S., Pryma, D. A. Tags: INVITED PERSPECTIVE Source Type: research
Impact of Single-Time-Point Estimates of 177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
Conclusion: Estimated radiation ADs and patient management decisions were similar with the STP and MTP models. The STP model can simplify the dosimetry process while also reducing scanner and staff time and improving patient comfort. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Chicheportiche, A., Sason, M., Zidan, M., Godefroy, J., Krausz, Y., Gross, D. J., Grozinsky-Glasberg, S., Ben-Haim, S. Tags: Clinical Investigations Source Type: research
Stacking Ensemble Learning-Based [18F]FDG PET Radiomics for Outcome Prediction in Diffuse Large B-Cell Lymphoma
Conclusion: The combined model that incorporates [18F]FDG PET radiomics and clinical characteristics based on stacking ensemble learning could enable improved risk stratification in DLBCL. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - October 3, 2023 Category: Nuclear Medicine Authors: Zhao, S., Wang, J., Jin, C., Zhang, X., Xue, C., Zhou, R., Zhong, Y., Liu, Y., He, X., Zhou, Y., Xu, C., Zhang, L., Qian, W., Zhang, H., Zhang, X., Tian, M. Tags: Clinical Investigations Source Type: research
